Rothschild & Co. Asset Management US Inc. reduced its position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 2.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 836,028 shares of the specialty pharmaceutical company’s stock after selling 21,092 shares during the period. Rothschild & Co. Asset Management US Inc.’s holdings in Supernus Pharmaceuticals were worth $42,094,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Glenmede Trust Co. NA raised its position in Supernus Pharmaceuticals by 3.2% in the 2nd quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock valued at $39,070,000 after buying an additional 20,012 shares during the last quarter. Icon Advisers Inc. Co. purchased a new stake in Supernus Pharmaceuticals in the 3rd quarter valued at $3,877,000. Oppenheimer Asset Management Inc. raised its position in Supernus Pharmaceuticals by 9.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock valued at $746,000 after buying an additional 1,251 shares during the last quarter. Cynosure Advisors LLC raised its position in Supernus Pharmaceuticals by 55.0% in the 2nd quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock valued at $494,000 after buying an additional 2,930 shares during the last quarter. Finally, SevenBridge Financial Group LLC purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $113,000. Institutional investors own 97.83% of the company’s stock.
A number of equities research analysts recently commented on the company. Zacks Investment Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 8th. BidaskClub lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 7th. Piper Jaffray Companies reissued a “hold” rating and issued a $44.00 price target on shares of Supernus Pharmaceuticals in a research report on Thursday, August 9th. ValuEngine raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, September 19th. Finally, Jefferies Financial Group raised their target price on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $56.00.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.09. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. The firm had revenue of $102.99 million during the quarter, compared to analyst estimates of $100.75 million. During the same period last year, the firm posted $0.29 EPS. The business’s revenue was up 28.1% compared to the same quarter last year. Equities analysts expect that Supernus Pharmaceuticals Inc will post 1.87 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Rothschild & Co. Asset Management US Inc. Sells 21,092 Shares of Supernus Pharmaceuticals Inc (SUPN)” was first posted by WKRB News and is the sole property of of WKRB News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.wkrb13.com/2018/11/25/rothschild-co-asset-management-us-inc-sells-21092-shares-of-supernus-pharmaceuticals-inc-supn.html.
Supernus Pharmaceuticals Profile
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Recommended Story: Understanding the different types of bonds
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.